Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. (Q50619591)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 September 2008

Language	Label	Description	Also known as
English	Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.	scientific article published on 24 September 2008

Statements

scholarly article

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. (English)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

vector-borne disease

0 references

author name string

Roderick S Tang

1

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Richard R Spaete

2

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Mark W Thompson

3

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Mia MacPhail

4

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Jeanne M Guzzetta

5

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Patricia C Ryan

6

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Keith Reisinger

7

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Patricia Chandler

8

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Milo Hilty

9

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Robert E Walker

10

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Margarita M Gomez

11

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Genevieve A Losonsky

12

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

language of work or name

0 references

publication date

24 September 2008

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

26

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

50

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

6373-6382

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.09.018

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50619591&oldid=1775333365"